Melatonin : clinical perspectives in neurodegeneration

Abstract: Prevention of neurodegenerative diseases is presently a major goal for our Society and melatonin, an unusual phylogenetically conserved molecule present in all aerobic organisms, merits consideration in this respect. Melatonin combines both chronobiotic and cytoprotective properties. As a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Cardinali, Daniel Pedro
Formato: Artículo
Lenguaje:Inglés
Publicado: Frontiers 2019
Materias:
ENFERMEDAD DE ALZHEIMER
ENFERMEDAD DE PARKINSON
ENFERMEDADES NEUROGENERATIVAS
ENVEJECIMIENTO
MELATONINA
NEURODEGENERACION
ESTRES OXIDATIVO
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/8802
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139123456789-8802
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic ENFERMEDAD DE ALZHEIMER
ENFERMEDAD DE PARKINSON
ENFERMEDADES NEUROGENERATIVAS
ENVEJECIMIENTO
MELATONINA
NEURODEGENERACION
ESTRES OXIDATIVO
spellingShingle ENFERMEDAD DE ALZHEIMER
ENFERMEDAD DE PARKINSON
ENFERMEDADES NEUROGENERATIVAS
ENVEJECIMIENTO
MELATONINA
NEURODEGENERACION
ESTRES OXIDATIVO
Cardinali, Daniel Pedro
Melatonin : clinical perspectives in neurodegeneration
topic_facet ENFERMEDAD DE ALZHEIMER
ENFERMEDAD DE PARKINSON
ENFERMEDADES NEUROGENERATIVAS
ENVEJECIMIENTO
MELATONINA
NEURODEGENERACION
ESTRES OXIDATIVO
description Abstract: Prevention of neurodegenerative diseases is presently a major goal for our Society and melatonin, an unusual phylogenetically conserved molecule present in all aerobic organisms, merits consideration in this respect. Melatonin combines both chronobiotic and cytoprotective properties. As a chronobiotic, melatonin can modify phase and amplitude of biological rhythms. As a cytoprotective molecule, melatonin reverses the low degree inflammatory damage seen in neurodegenerative disorders and aging. Low levels of melatonin in blood characterizes advancing age. In experimental models of Alzheimer's disease (AD) and Parkinson's disease (PD) the neurodegeneration observed is prevented by melatonin. Melatonin also increased removal of toxic proteins by the brain glymphatic system. A limited number of clinical trials endorse melatonin's potentiality in AD and PD, particularly at an early stage of disease. Calculations derived from animal studies indicate cytoprotective melatonin doses in the 40-100 mg/day range. Hence, controlled studies employing melatonin doses in this range are urgently needed. The off-label use of melatonin is discussed.
format Artículo
author Cardinali, Daniel Pedro
author_facet Cardinali, Daniel Pedro
author_sort Cardinali, Daniel Pedro
title Melatonin : clinical perspectives in neurodegeneration
title_short Melatonin : clinical perspectives in neurodegeneration
title_full Melatonin : clinical perspectives in neurodegeneration
title_fullStr Melatonin : clinical perspectives in neurodegeneration
title_full_unstemmed Melatonin : clinical perspectives in neurodegeneration
title_sort melatonin : clinical perspectives in neurodegeneration
publisher Frontiers
publishDate 2019
url https://repositorio.uca.edu.ar/handle/123456789/8802
work_keys_str_mv AT cardinalidanielpedro melatoninclinicalperspectivesinneurodegeneration
bdutipo_str Repositorios
_version_ 1764820528557719552

Ejemplares similares